Corcept Therapeutics Incorporated (CORT)
Largest Insider Buys in Sector
CORT Stock Price History Chart
CORT Stock Performance
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients …
Insider Activity of Corcept Therapeutics Incorporated
Over the last 12 months, insiders at Corcept Therapeutics Incorporated have bought $0 and sold $9.44M worth of Corcept Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Corcept Therapeutics Incorporated have bought $2.34M and sold $8.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $3.23M was made by BAKER G LEONARD JR (director) on 2021‑06‑11.
List of Insider Buy and Sell Transactions, Corcept Therapeutics Incorporated
| 2024-12-10 | Sale | director | 2,200 0.0021% | $59.46 | $130,812 | -5.77% | ||
| 2024-11-22 | Sale | Chief Business Officer | 2,609 0.0024% | $56.20 | $146,626 | +2.21% | ||
| 2024-11-22 | Sale | See Remarks | 1,411 0.0013% | $56.72 | $80,032 | +2.21% | ||
| 2024-11-11 | Sale | director | 2,200 0.0021% | $59.88 | $131,736 | -2.15% | ||
| 2024-11-04 | Sale | Chief Development Officer | 3,394 0.0032% | $48.97 | $166,204 | +15.44% | ||
| 2024-10-01 | Sale | Chief Business Officer | 11,000 0.0113% | $46.28 | $509,080 | +17.05% | ||
| 2024-10-01 | Sale | Chief Development Officer | 10,000 0.0102% | $46.28 | $462,800 | +17.05% | ||
| 2024-09-03 | Sale | Chief Development Officer | 10,000 0.0099% | $35.30 | $353,000 | +41.83% | ||
| 2024-08-26 | Sale | Chief Business Officer | 3,101 0.003% | $35.71 | $110,737 | +35.06% | ||
| 2024-08-01 | Sale | Chief Development Officer | 10,000 0.0098% | $38.67 | $386,700 | +20.98% | ||
| 2024-08-01 | Sale | director | 150 0.0001% | $38.50 | $5,775 | +20.98% | ||
| 2024-07-01 | Sale | Chief Business Officer | 11,000 0.0109% | $32.49 | $357,390 | 0.00% | ||
| 2024-07-01 | Sale | See Remarks | 5,000 0.0049% | $32.49 | $162,452 | 0.00% | ||
| 2024-07-01 | Sale | Chief Development Officer | 10,000 0.0099% | $32.49 | $324,900 | 0.00% | ||
| 2024-07-01 | Sale | director | 2,200 0.0022% | $32.81 | $72,182 | 0.00% | ||
| 2024-06-03 | Sale | See Remarks | 5,000 0.0046% | $30.18 | $150,916 | +30.73% | ||
| 2024-06-03 | Sale | Chief Development Officer | 10,000 0.0098% | $32.00 | $320,000 | +30.73% | ||
| 2024-06-03 | Sale | director | 2,200 0.002% | $30.21 | $66,462 | +30.73% | ||
| 2024-05-28 | Sale | Chief Business Officer | 11,000 0.0102% | $30.39 | $334,294 | +21.70% | ||
| 2024-05-28 | Sale | Chief Development Officer | 30,000 0.0292% | $32.00 | $960,000 | +21.70% |
Insider Historical Profitability
| Robb Gary Charles | Chief Business Officer | 20163 0.0192% | $50.78 | 1 | 26 | +72.23% |
| ALTA BIOPHARMA PARTNERS II LP | 10 percent owner | 5484063 5.2341% | $50.78 | 2 | 0 | +16.86% |
| PENHOET EDWARD | 5484063 5.2341% | $50.78 | 1 | 0 | +78.79% | |
| SUTTER HILL VENTURES | 10 percent owner | 5217464 4.9797% | $50.78 | 6 | 0 | +59.94% |
| MARDUEL ALIX | 10 percent owner | 5043299 4.8135% | $50.78 | 3 | 0 | +59.16% |
Institutional Investor Ownership
| BlackRock | $423.85M | 16.16 | 16.83M | +2.55% | +$10.54M | 0.01 | |
| The Vanguard Group | $240.96M | 9.19 | 9.57M | +0.3% | +$711,617.50 | <0.01 | |
| Ingalls Snyder Llc | $209.16M | 7.98 | 8.3M | -0.58% | -$1.23M | 9.78 | |
| Renaissance Technologies | $179.31M | 6.84 | 7.12M | +5.84% | +$9.89M | 0.29 | |
| Parallel Advisors, LLC | $96.12M | 3.67 | 3.82M | +1.26% | +$1.19M | 2.62 |